Find a therapist to help with ADHD

Simtriyo, approved in July 2026, spares dopamine and disrupts sleep less, but its benefit is smaller.

Qelbree starts working faster than Strattera; generic Vyvanse may matter more than any new drug.

If your current medication works, new options ask nothing of you. If it doesn’t, start by asking why.

Three ADHD medications have reached American patients in the past five years, and a fourth was approved this July. For a field that spent two decades cycling the same molecules through new delivery systems, that is a genuinely unusual stretch. It has also produced a wave of questions in my office, most of which reduce to one: Should I switch?

For most patients the answer is No, and understanding why requires knowing what each new option actually is.

Simtriyo (centanafadine) is the newest, approved by the FDA in July 2026 for ages six and up. It works mainly on norepinephrine, one of the two brain chemicals the older stimulants act on, while largely leaving dopamine alone. That design has a purpose: Dopamine is where the euphoria and abuse potential of amphetamines comes from, so a medication that sidesteps it may carry less of both. The trade-off shows up in the trial data. In........

© Psychology Today